Serial C-reactive protein measurements in patients treated for suspected abdominal tuberculosis

Sharma, Vishal; Mandavdhare, Harshal; Lamoria, Sandeep; Singh, Harjeet; Kumar, Amit

doi:10.1016/j.dld.2017.12.008

Cited by 45 publications

(36 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We previously reported that pulmonary TB displayed heightened serum CRP levels compared with latent TB and extrapulmonary TB . Previously published data also indicate that circulating CRP levels were significantly increased in active TB disease compared with controls . During M. tuberculosis infection, CRP levels are increased in TB patients starting ATT and decreased during the first 2 months of treatment, and these elevated CRP levels reflected higher AFB smear grades and correlated with disease severity .…”

Section: Discussionmentioning

confidence: 81%

Elevated circulating levels of monocyte activation markers among tuberculosis patients with diabetes co‐morbidity

et al. 2018

View full text Add to dashboard Cite

Alteration in the frequency of monocyte subsets is a hallmark of tuberculosis-diabetes co-morbidity (TB-DM). To study this association, we examined the plasma levels of sCD14, sCD163, C-reactive protein (CRP) and soluble tissue factor (sTF) in individuals with TB-DM, TB or diabetes mellitus (DM), and in healthy controls (HC). Circulating levels of sCD14, sCD163 and sTF were significantly increased in TB-DM and DM compared with TB and HC; however, CRP was significantly increased in TB-DM and TB compared with DM and HC. During longitudinal follow up, sCD14, CRP and sTF levels remained significantly increased in TB-DM compared with TB from baseline (pre-treatment), during treatment (2nd month) and at the completion (6th month) of anti-TB treatment (ATT), whereas sCD163 was significantly higher in TB-DM compared with TB only at baseline. Moreover, the levels of sCD14 and sCD163 were significantly higher in TB-DM individuals with bilateral and cavitary disease and exhibited a significant positive relationship with bacterial burden. Levels of sCD14, sCD163 and CRP exhibited a positive relationship with HbA1c levels. Within the TB-DM group, those with known diabetes before incident TB (KDM) exhibited significantly higher levels of sCD14 and sCD163 compared with individuals with newly diagnosed DM with TB (NDM). Finally, KDM individuals on metformin treatment exhibited significantly lower levels of sCD14, sCD163 and CRP compared with those on non-metformin-containing regimens. Our data demonstrate that systemic monocyte activation marker levels reflect baseline disease severity and extent in TB-DM, differentiate KDM from NDM and are modulated by ATT and metformin therapy.

show abstract

Section: Discussionmentioning

confidence: 81%

Elevated circulating levels of monocyte activation markers among tuberculosis patients with diabetes co‐morbidity

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Children diagnosed with ATB were divided into two groups based on their diagnosis “Confirmed case of abdominal tuberculosis”—diagnosis based on the bacteriological identification of Mycobacterium tuberculosis through Ziehl‐Neelsen acid‐fast stain and/or culture and/or polymerase chain reaction (PCR)‐based assays or the presence of caseating granulomas on histology. PCR data were available from 2015 onward.…”

Section: Methodsmentioning

confidence: 99%

“…The endoscopic dilatation of intestinal (ileal-1, descending colon-1) strictures were performed in two patients. All patients received ATT for a median duration of 12 (9)(10)(11)(12)(13)(14)(15)(16)(17)(18) months. Fifteen (6.8%) patients developed ATT-induced hepatitis and required modification of treatment.…”

Section: Strength Of Diagnosismentioning

confidence: 99%

Abdominal tuberculosis in children: A real‐world experience of 218 cases from an endemic region

et al. 2019

View full text Add to dashboard Cite

Background and Aim Abdominal tuberculosis (ATB) in children poses a diagnostic challenge because of its nonspecific clinical features, which often delay the diagnosis. Our aim was to present our real‐world experience and provide an insight into the presentation, pattern of distribution, and diagnosis of the disease. Methods A retrospective review was conducted of case records of all children ≤12 years of age diagnosed with ATB from January 2007 to January 2018. Clinical details and investigations were recorded and analyzed. Results A total of 218 children (110 boys), with a median age of 10 (0.25–12) years, were included. There was a median delay of 4 (0.5–36) months in establishing the diagnosis. Abdominal pain, fever, and loss of weight were the most common presenting features, with the triad of symptoms present in 54%. Multiple intra‐abdominal sites were involved in 118 (54%) patients, with a combination of the gastrointestinal tract (I) and abdominal lymph nodes (L) being the most common (53/118). Among children with single‐site involvement (n = 100), the most commonly involved was L in 39 (39%), followed by I in 35(35%). Loss of weight was more common in children with involvement of multiple sites (85/118 vs 60/100, P = 0.03). Overall, a confirmed diagnosis was possible in 94 participants (43.1%). Suggestive imaging had the highest diagnostic yield of 85%. Nine (4.1%) patients needed surgical management. Conclusion A triad of abdominal pain, fever, and weight loss is suggestive of ATB. Multiple intra‐abdominal sites are frequently involved. Microbiological confirmation is possible in only one‐third of the cases.

show abstract

“…Clinical symptoms of CD and an elevated CRP level are consistent with disease recurrence (147). However, CRP is not disease specific, and elevated levels occur in non-IBD enteritis, inflammatory disorders not related to the gastrointestinal tract, tissue damage, diabetes, malignancies, and cardiovascular disease (148)(149)(150)(151)(152). The sensitivity of CRP measurement is also limited with respect to IBD; normal CRP levels can be seen in patients with active IBD (153).…”

Section: Surveillance Of Disease Activity C-reactive Proteinmentioning

confidence: 99%

Serum Biomarkers for Inflammatory Bowel Disease

et al. 2020

View full text Add to dashboard Cite

Background: Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is a chronic, inflammatory disorder of the gastrointestinal tract. As the novel therapeutic goal and biologicals are widely recognized, accurate assessment of disease and prediction of therapeutic response have become a crucial challenge in clinical practice. Also, because of the continuously rising incidence, convenient and economical methods of diagnosis and clinical assessment are urgently needed. Recently, serum biomarkers have made a great progress and become a focus in IBD study because they are non-invasive, convenient, and relatively inexpensive than are markers in biopsy tissue, stool, breath, and other body fluids. Aims: To review the available data on serological biomarkers for IBD. Methods: We searched PubMed using predefined key words on relevant literatures of serum biomarkers regarding diagnosis, evaluation of therapeutic efficacy, surveillance of disease activity, and assessment of prognosis for IBD. Results: We reviewed serological biomarkers that are well-established and widely used (e.g., C-reactive protein), newly discovered biomarkers (e.g., cytokines, antibodies, and non-coding RNAs), and also recently advancements in serological biomarkers (e.g., metabolomics and proteomics) that are used in different aspects of IBD management. Conclusions: With such a wealth of researches, to date, there are still no ideal serum biomarkers for IBD. Serum profiling and non-coding RNAs are just starting to blossom but reveal great promise for future clinical practice. Combining different biomarkers can be valuable in improving performance of disease evaluation.

show abstract

Serial C-reactive protein measurements in patients treated for suspected abdominal tuberculosis

Cited by 45 publications

References 16 publications

Elevated circulating levels of monocyte activation markers among tuberculosis patients with diabetes co‐morbidity

Elevated circulating levels of monocyte activation markers among tuberculosis patients with diabetes co‐morbidity

Abdominal tuberculosis in children: A real‐world experience of 218 cases from an endemic region

Serum Biomarkers for Inflammatory Bowel Disease

Contact Info

Product

Resources

About